Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Covidien looks to FY09 restructure to savecosts

This article was originally published in Clinica

Executive Summary

Healthcare products providerCovidien is to launch a restructuring plan in the new fiscal year, starting in October, in a bid to improve its cost structure and enhance operational growth. The programme will be implemented across all four business segments – devices, imaging, pharma and medical supplies- and at corporate level. While the restructuring will result in the Hamilton, Bermuda-based company being hit by $200m in pre-tax charges for the first quarter of fiscal 2009, it will benefit from annualised cost savings of around $50-75m once the programme is completed, said the firm. President and CEO Richard Meelia said the company remains committed to expanding into “high-growth areas of the healthcare market”.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel